Abstract
Duplication of an AR enhancer occurs in most patients with CRPC and promotes disease progression.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
August 2018
Volume 8, Issue 8
Volume 8, Issue 8
AR Enhancer Amplification Drives Castration-Resistant Prostate Cancer
Jump to section
Advertisement